Climb Bio Inc (NASDAQ:CLYM) price closed lower on Tuesday, January 14, and dropping -2.60% below its previous close.
A look at the daily price movement shows that the last close reads $1.92, with intraday deals fluctuated between $1.79 and $1.99. The company’s 5Y monthly beta was ticking -0.336. Taking into account the 52-week price action we note that the stock hit a 52-week high of $11.55 and 52-week low of $1.73. The stock subtracted -39.68% on its value in the past month.
Climb Bio Inc, which has a market valuation of $125.71 million, is expected to release its quarterly earnings report in February.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give CLYM a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
The overview shows that CLYM’s price is at present -10.04% off the SMA20 and -33.46% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 36.90, with weekly volatility standing at 11.77%. The indicator jumps to 12.41% when calculated based on the past 30 days. Climb Bio Inc (NASDAQ:CLYM)’s beta value is holding at -0.26, while the average true range (ATR) indicator is currently reading 0.25.
An analysis of the Climb Bio Inc (NASDAQ:CLYM) stock in terms of its daily trading volume indicates that the 3-month average is 346.89K. However, this figure increases on the past 10-day timeline to an average of 0.49 million.
Current records show that the company has 67.22M in outstanding shares. The insiders’ percentage holdings are 23.44% of outstanding shares while the percentage share held by institutions stands at 71.05%. The stats also highlight that short interest as of 2024-12-31, stood at 4.82 million shares, which puts the short ratio at the time at 13.74. From this we can glean that short interest is 988.00 of company’s current outstanding shares. Notably, we see that shares short in December fall slightly given the previous month’s figure stood at 4.9 million. But the 3.89% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
